Holding(s) in Company

Allergy Therapeutics PLC
05 February 2007

Allergy Therapeutics plc

Holding in Company

Allergy Therapeutics plc (the "Company") received notification on 31 January
2007 from AXA Investment Managers UK Ltd that, following a purchase of 6,029,620
ordinary shares of 0.1 pence each ("Ordinary Shares"), AXA S.A. and its group
companies are interested in 6,029,620 Ordinary Shares, comprising a beneficial
interest of 2,500,000 Ordinary Shares and a non-beneficial interest of 3,529,620
Ordinary Shares, representing 7.36 per cent. of the Company's issued share
capital of 81,950,632 Ordinary Shares, as detailed below:

Company / Fund                                                  Holding              %

AXA Framlington Xerox Final Salary Pension Scheme               447,250              0.55
(Non-beneficial)
AXA Framlington Islington Group Pension Scheme                  280,832              0.34
(Non-beneficial)
AXA Framlington SEI UK Equity                                   450,000              0.55
(Non-beneficial)
AXA Framlington Throgmorton Trust                               2,500,000            3.05
(Beneficial)
AXA Framlington UK Smaller Companies                            1,600,000            1.95
(Non-beneficial)
AXA Framlington Biotech                                         283,200              0.35
(Non-beneficial)
AXA Framlington BAE Systems Pensions Fund CIF Trustees          325,644              0.40
(Non-beneficial)
AXA Framlington BAE Systems 2000 Pensions Fund                  142,694              0.17
(Non-beneficial)

Total                                                           6,029,620            7.36%




                      This information is provided by RNS
            The company news service from the London Stock Exchange     
HOLUVRVRBORURAR